Membrane Topology Mapping of Vitamin K Epoxide Reductase by in Vitro Translation/Cotranslocation*

Vitamin K epoxide reductase (VKOR) catalyzes the conversion of vitamin K 2,3-epoxide into vitamin K in the vitamin K redox cycle. Recently, the gene encoding the catalytic subunit of VKOR was identified as a 163-amino acid integral membrane protein. In this study we report the experimentally derived membrane topology of VKOR. Our results show that four hydrophobic regions predicted as the potential transmembrane domains in VKOR can individually insert across the endoplasmic reticulum membrane in vitro. However, in the intact enzyme there are only three transmembrane domains, residues 10–29, 101–123, and 127–149, and membrane-integration of residues 75–97 appears to be suppressed by the surrounding sequence. Results of N-linked glycosylation-tagged full-length VKOR shows that the N terminus of VKOR is located in the endoplasmic reticulum lumen, and the C terminus is located in the cytoplasm. Further evidence for this topological model of VKOR was obtained with freshly prepared intact microsomes from insect cells expressing HPC4-tagged full-length VKOR. In these experiments an HPC4 tag at the N terminus was protected from proteinase K digestion, whereas an HPC4 tag at the C terminus was susceptible. Altogether, our results suggest that VKOR is a type III membrane protein with three transmembrane domains, which agrees well with the prediction by the topology prediction program TMHMM.

[1]  H. Thijssen,et al.  Microsomal lipoamide reductase provides vitamin K epoxide reductase with reducing equivalents. , 1994, The Biochemical journal.

[2]  C. Nicchitta,et al.  A topological study of the human γ-glutamyl carboxylase , 2000 .

[3]  J. J. Lee,et al.  Metabolism of vitamin K and vitamin K 2,3-epoxide via interaction with a common disulfide. , 1984, Biochemistry.

[4]  R. Bell,et al.  Vitamin K activity of phylloquinone oxide. , 1970, Archives of biochemistry and biophysics.

[5]  G von Heijne,et al.  Consensus predictions of membrane protein topology , 2000, FEBS letters.

[6]  Gunnar von Heijne,et al.  Topology Models for 37 Saccharomyces cerevisiaeMembrane Proteins Based on C-terminal Reporter Fusions and Predictions* , 2003, The Journal of Biological Chemistry.

[7]  D. Sane,et al.  Vitamin K 2,3-epoxide reductase and the vitamin K-dependent γ-carboxylation system , 2002 .

[8]  S. Hutson,et al.  Assembly of the Warfarin-sensitive Vitamin K 2,3-Epoxide Reductase Enzyme Complex in the Endoplasmic Reticulum Membrane* , 1997, The Journal of Biological Chemistry.

[9]  A. Holmgren,et al.  Stimulation of the dithiol-dependent reductases in the vitamin K cycle by the thioredoxin system. Strong synergistic effects with protein disulphide-isomerase. , 1992, The Biochemical journal.

[10]  R. Wallin,et al.  Rat and human liver vitamin K epoxide reductase: inhibition by thiol blockers and vitamin K1. , 1987, The International journal of biochemistry.

[11]  V. Goder,et al.  Topogenesis of membrane proteins: determinants and dynamics , 2001, FEBS letters.

[12]  T. Stanley,et al.  Expression and Characterization of the Naturally Occurring Mutation L394R in Human γ-Glutamyl Carboxylase* , 2000, The Journal of Biological Chemistry.

[13]  D. Smalley,et al.  Vitamin K1 2,3-epoxide and quinone reduction: mechanism and inhibition. , 1990, Free radical research communications.

[14]  A. Krogh,et al.  Reliability measures for membrane protein topology prediction algorithms. , 2003, Journal of molecular biology.

[15]  J. Suttie,et al.  Studies of the vitamin K-dependent carboxylase and vitamin K epoxide reductase in rat liver. , 1986, Haemostasis.

[16]  P. Preusch Is thioredoxin the physiological vitamin K epoxide reducing agent? , 1992, FEBS letters.

[17]  E. Israels,et al.  Novel vitamin K-dependent pathways regulating cell survival , 2001, Apoptosis.

[18]  G von Heijne,et al.  Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane. , 1993, The Journal of biological chemistry.

[19]  D. Stafford,et al.  The Vitamin K-dependent Carboxylase , 2002, Thrombosis and Haemostasis.

[20]  Rolf Apweiler,et al.  Evaluation of methods for the prediction of membrane spanning regions , 2001, Bioinform..

[21]  C. Esmon,et al.  The interaction of a Ca2+-dependent monoclonal antibody with the protein C activation peptide region. Evidence for obligatory Ca2+ binding to both antigen and antibody. , 1988, The Journal of biological chemistry.

[22]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[23]  Terri K. Attwood,et al.  BPROMPT: a consensus server for membrane protein prediction , 2003, Nucleic Acids Res..

[24]  D. Cowell,et al.  Characterization and purification of the vitamin K1 2,3 epoxide reductase system from rat liver , 2001 .

[25]  B. Furie,et al.  Vitamin K-Dependent Biosynthesis of γ-Carboxyglutamic Acid , 1999 .

[26]  T. Guenthner,et al.  Purification of warfarin-sensitive vitamin K epoxide reductase. , 1997, Methods in enzymology.

[27]  A. Khvorova,et al.  Identification of the gene for vitamin K epoxide reductase , 2004, Nature.

[28]  G. Blobel,et al.  Preparation of microsomal membranes for cotranslational protein translocation. , 1983, Methods in enzymology.

[29]  J. J. Lee,et al.  Identification of a warfarin-sensitive protein component in a 200S rat liver microsomal fraction catalyzing vitamin K and vitamin K 2,3-epoxide reduction. , 1985, Biochemistry.

[30]  K. Becker,et al.  The thioredoxin system—From science to clinic , 2004, Medicinal research reviews.

[31]  C. Schneider,et al.  The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade , 1993, Molecular and cellular biology.

[32]  R. Silverman,et al.  Reduced thioredoxin: a possible physiological cofactor for vitamin K epoxide reductase. Further support for an active site disulfide. , 1988, Biochemical and biophysical research communications.

[33]  P. Price Role of vitamin-K-dependent proteins in bone metabolism. , 1988, Annual review of nutrition.

[34]  Ylva Gavel,et al.  Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering , 1990, Protein engineering.

[35]  C. Ponting,et al.  Vitamin K epoxide reductase: homology, active site and catalytic mechanism. , 2004, Trends in biochemical sciences.

[36]  D. Sane,et al.  Engineering of a Recombinant Vitamin K-dependent γ-Carboxylation System with Enhanced γ-Carboxyglutamic Acid Forming Capacity , 2005, Journal of Biological Chemistry.

[37]  A. Sweatt,et al.  A molecular mechanism for genetic warfarin resistance in the rat , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  G. von Heijne,et al.  Proline-induced disruption of a transmembrane alpha-helix in its natural environment. , 1998, Journal of molecular biology.

[39]  R. Silverman,et al.  Purification of a vitamin K epoxide reductase that catalyzes conversion of vitamin K 2,3-epoxide to 3-hydroxy-2-methyl-3-phytyl-2,3-dihydronaphthoquinone. , 1985, Proceedings of the National Academy of Sciences of the United States of America.